Mazor signed commercial agreements with Medtronic last May, giving Medtronic exclusive distribution rights for new Mazor spine products in exchange for roughly $52 million in total potential investment.
In the first stage of the investment, Medtronic paid $11.9 million for 4 percent of Mazor’s shares.
Mazor’s launch of the new Mazor X System will trigger Medtronic’s second-stage investment of up to $20 million.
The third stage of investment, also reaching a potential of $20 million, is contingent upon several terms, including the establishment of a global distribution agreement between the two companies.
More articles on supply chain:
GE stakes claim on cell therapy market with Biosafe acquisition
10 costliest medical conditions
FDA Commissioner: US needs improved system to track medical device issues
Becker’s 3rd Annual Fall Chief Pharmacy Officer Summit is the top tier event that the people leading the future of pharmacy convene. This 3-day event is built specifically for Chief Pharmacy Officers and senior pharmacy leaders. The sessions examine the workforce, financial and clinical priorities shaping pharmacy today. Becker’s is where candid discussions flourish and new ideas thrive. Becker's 3rd Annual Fall Chief Pharmacy Officer Summit
